Cost–benefit evaluation of routine influenza immunisation in people 65–74 years of age

S Allsup¹
M Gosney¹*
A Haycox²
M Regan³

¹ Department of Geriatric Medicine, University of Liverpool, UK
² Department of Pharmacology and Therapeutics, University of Liverpool, UK
³ Liverpool Health Authority, UK

* Corresponding author

Executive summary

Health Technology Assessment 2003; Vol. 7: No. 24
Objectives
To determine the cost-effectiveness of influenza vaccination in people aged 65–74 years in the absence of co-morbidity.

Design
Primary research: randomised controlled trial.

Setting
Primary care.

Subjects
People without risk factors for influenza (diabetes, asthma, chronic heart, lung or renal disease, immunosuppression or living in an institution) or contraindications to vaccination were identified from 20 general practitioner (GP) practices in Liverpool in September 1999 and invited to participate in the study. There were 5875/9727 (60.4%) people aged 65–74 years identified as potentially eligible for entry into the study and, of these, 729 (12%) were randomised. The remaining 39.6% of people in this age group had one or more risk factors for influenza making them eligible for vaccination according to guidance from the Department of Health and so could not be included in this study.

Intervention
Participants were randomised in a ratio of 3:1 to receive either influenza vaccine or placebo (physiological saline solution), with all individuals receiving pneumococcal vaccine unless administered in the previous 10 years. Of the 729 people randomised, 552 received vaccine and 177 received placebo; 726 individuals were administered pneumococcal vaccine. Influenza vaccine was manufactured in accordance with the WHO recommendation (Northern Hemisphere) for 1999–2000 and contained the following antigens: A/Beijing/262/95 (H1N1), A/Sydney/5/97 (H3N2) and B/Beijing/184/93.

Main outcome measures
GP attendance with influenza-like illness (ILI) or pneumonia (primary outcome measure); GP attendance with respiratory symptoms; hospitalisation with a respiratory illness; death; participant self-reported ILI; quality of life (QoL) measures (EuroQoL EQ-5D and Hospital Anxiety and Depression scale) at 2, 4 and 6 months post-study vaccination; adverse reactions 3 days after vaccination. All outcome measures were recorded between 1 October 1999 and 31 March 2000.

Methodology of economic evaluation
The economic analysis was undertaken from a societal perspective and incorporated both public and privately borne costs associated with the vaccination programme. A cost-effectiveness analysis was undertaken to identify the incremental cost associated with the avoidance of episodes of influenza in the vaccination population. As many episodes of influenza may not lead to a GP consultation (sufferers simply ‘take to their bed’), a patient-held diary was employed to identify such ‘invisible’ episodes of ILI. An impact model was used to extrapolate the cost-effectiveness results obtained from the trial to assess their generalisability throughout the NHS.

Results
Background influenza rate
The background influenza rate in Liverpool in 1999–2000 was very similar to the overall rate in England and Wales where weekly consultations for influenza and ILI remained at baseline levels (less than 50 per 100,000 population) until week 50/1999 and then increased rapidly, peaking during week 2/2000 with a rate of 251/100,000. This rate fell within the range of ‘higher than expected seasonal activity’ of 200–400/100,000. Rates then quickly declined, returning to baseline levels by week 5/2000. The predominant circulating strain during this period was influenza A (H3N2).
Clinical outcome

Five (0.9%) people in the vaccine group were diagnosed by their GP with an ILI compared to two (1.1%) in the placebo group [relative risk (RR), 0.8; 95% confidence interval (CI) = 0.16 to 4.1]. No participants were diagnosed with pneumonia by their GP and there were no hospitalisations for respiratory illness in either group. Significantly fewer vaccinated individuals self-reported a single ILI (4.6% vs 8.9%, RR, 0.51; 95% CI for RR, 0.28 to 0.96). There was no significant difference in any of the QoL measurements over time between the two groups. Reported systemic side-effects (feverishness, aching limbs, fatigue, rash, cough, runny nose, headache and sore throat) showed no significant differences between groups. Local side-effects occurred with a significantly increased incidence in the vaccine group (11.3% vs 5.1%, p = 0.02).

Economic evaluation

Each GP consultation avoided by vaccination was estimated from trial data to generate a net NHS cost of £174.

Conclusions

No difference was seen between groups for the primary outcome measure (GP attendance with ILI or pneumonia), although the trial was underpowered to demonstrate a true difference. Vaccination had no significant effect on any of the QoL measures used, although vaccinated individuals were less likely to self-report ILI.

Implications for healthcare

Our analysis did not suggest that influenza vaccination in healthy people aged 65–74 years would lead to lower NHS costs. A significant protective effect of influenza vaccine was found for the reduction of self-reported ILI, but the study was not sufficiently powered to examine the effect of influenza vaccination on mortality, GP consultations for respiratory illness or hospital admissions for pneumonia- and influenza-associated respiratory illness.

Recommendations for future research

Following the introduction in 2000–1 of new Department of Health guidelines to include all people aged 65 years or more in the national vaccination programme, future research should look at ways to maximise vaccine uptake in people at greatest risk from influenza, especially older people (>80 years) and those living in nursing and residential accommodation. Research is also needed to investigate the level of vaccine protection afforded to people from different age and socio-economic populations.

Publication

The NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.

Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme.

This has meant that the HTA panels can now focus more explicitly on health technologies (‘health technologies’ are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care) rather than settings of care. Therefore the panel structure was replaced in 2000 by three new panels: Pharmaceuticals; Therapeutic Procedures (including devices and operations); and Diagnostic Technologies and Screening.

The HTA Programme will continue to commission both primary and secondary research. The HTA Commissioning Board, supported by the National Coordinating Centre for Health Technology Assessment (NCCHTA), will consider and advise the Programme Director on the best research projects to pursue in order to address the research priorities identified by the three HTA panels.

The research reported in this monograph was funded as project number 97/20/06.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors.

Criteria for inclusion in the HTA monograph series

Reports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA Programme Director: Professor Kent Woods
Series Editors: Professor Andrew Stevens, Dr Ken Stein, Professor John Gabbay, Dr Ruairidh Milne, Dr Chris Hyde and Dr Rob Riemisma
Monograph Editorial Manager: Sally Bailey and Sarah Llewellyn Lloyd

The editors and publisher have tried to ensure the accuracy of this report but do not accept liability for damages or losses arising from material published in this report. They would like to thank the referees for their constructive comments on the draft document.